<div class="embed-responsive embed-responsive-16by9"><iframe width="640" height="360" style="max-width: 100%;max-height: 100%; border:none;" src="https://oncologytube.com/channel/AnnualCancerMeeting/videoEmbed/28955/efficacy-tolerance-of-tak-788-patients-had-diarrhea-nausea-mild-rash-chemical-pancreatitis-appears-to-be-more-potent-specific-in-pre-clinical-studies?modestbranding=1&showinfo=1&autoplay=&controls=1&loop=&mute=&t=0&objectFit=" frameborder="0" allowfullscreen="allowfullscreen" allow="autoplay" scrolling="no">iFrame is not supported!</iframe></div>

Efficacy & Tolerance Of TAK-788: Patients Had Diarrhea, Nausea, Mild Rash, & Chemical Pancreatitis, Appears To Be Mor...

00:01:47

Annual Meeting

4 years 142 Views

Share Add to Report 0

Embed (Iframe):

<div class="embed-responsive embed-responsive-16by9"><iframe width="640" height="360" style="max-width: 100%;max-height: 100%; border:none;" src="https://oncologytube.com/channel/AnnualCancerMeeting/videoEmbed/28955/efficacy-tolerance-of-tak-788-patients-had-diarrhea-nausea-mild-rash-chemical-pancreatitis-appears-to-be-more-potent-specific-in-pre-clinical-studies?modestbranding=1&showinfo=1&autoplay=&controls=1&loop=&mute=&t=0&objectFit=" frameborder="0" allowfullscreen="allowfullscreen" allow="autoplay" scrolling="no">iFrame is not supported!</iframe></div>

Embed (Object):

<div class="embed-responsive embed-responsive-16by9"><object width="640" height="360"><param name="movie" value="https://oncologytube.com/channel/AnnualCancerMeeting/videoEmbed/28955/efficacy-tolerance-of-tak-788-patients-had-diarrhea-nausea-mild-rash-chemical-pancreatitis-appears-to-be-more-potent-specific-in-pre-clinical-studies?modestbranding=1&showinfo=1&autoplay=&controls=1&loop=&mute=&t=0&objectFit="></param><param name="allowFullScreen" value="true"></param><param name="allowscriptaccess" value="always"></param><embed src="https://oncologytube.com/channel/AnnualCancerMeeting/videoEmbed/28955/efficacy-tolerance-of-tak-788-patients-had-diarrhea-nausea-mild-rash-chemical-pancreatitis-appears-to-be-more-potent-specific-in-pre-clinical-studies?modestbranding=1&showinfo=1&autoplay=&controls=1&loop=&mute=&t=0&objectFit=" allowscriptaccess="always" allowfullscreen="true" width="640" height="360"></embed></object></div>

Link (HTML):

<a href="https://oncologytube.com/channel/AnnualCancerMeeting/video/28955"><img src="https://oncologytubecom.cdn.ypt.me/videos/video_190606053737_3d92/video_190606053737_3d92.jpg?cache=15669162341691419079">Efficacy & Tolerance Of TAK-788: Patients Had Diarrhea, Nausea, Mild Rash, & Chemical Pancreatitis, Appears To Be More Potent & Specific In Pre-Clinical Studies</a>

Link (BBCode):

[url=https://oncologytube.com/channel/AnnualCancerMeeting/video/28955][img]https://oncologytubecom.cdn.ypt.me/videos/video_190606053737_3d92/video_190606053737_3d92.jpg?cache=15669162341691419079[/img]Efficacy & Tolerance Of TAK-788: Patients Had Diarrhea, Nausea, Mild Rash, & Chemical Pancreatitis, Appears To Be More Potent & Specific In Pre-Clinical Studies[/url]

Sign in now!

Permanent Link

URL Friendly (SEO)

Current Time (SEO)

Category:

Non-Small Cell Lung Cancer

Description:

Joel Neal MD Of Stanford University Medical Center Discusses Efficacy & Tolerance Of TAK-788: Patients Had Diarrhea, Nausea, Mild Rash, & Chemical Pancreatitis, Appears To Be More Potent & Specific In Pre-Clinical Studies.